SAN DIEGO--(BUSINESS WIRE)--Micronoma announced today that it is serving as the industry partner on a grant the NYU Grossman School of Medicine received from the National Cancer Institute to identify microbial and host genomic signatures that can be used with other methodologies to predict non-small cell lung cancer (NSCLC) in its early stages as well as the chance of post-surgical recurrence.
“Micronoma is thrilled to partner again with NYU researchers to advance the cause of using microbial biomarkers to diagnose cancer as early as possible as well as establish potential recurrence markers,” said Micronoma CEO and co-founder Sandrine Miller-Montgomery. “Lung cancer remains the leading cancer killer and the development of non-invasive methods to identify it is key to improving patient outcomes.”
“This work will build on our groundbreaking work as the first biotech company offering early cancer detection using OncobiotaLUNG, a microbiome-driven liquid biopsy platform,” she added.
Micronoma and NYU Langone Health are currently collaborating to use blood samples to derive multi-omics, including circulating tumor microbial DNA associated with early lung cancer diagnosis, which the company should make commercially available under CLIA regulations later this year.
With this grant, NYU and Micronoma intend to continue identifying the leading microbial and host biomarkers that can be used to predict early-stage lung cancer diagnosis and prognosis and use cutting-edge bioinformatic mechanisms and potentially targeted molecular tools to pursue developing early-stage testing and prognosis.
“We are extremely excited to bring a novel use of microbial genomic signatures as a potential biomarker for early-stage lung cancer to the Early Detection Research Network (EDRN) multicenter consortium,” said Leopoldo N. Segal, M.D., Associate Professor of Medicine at NYU Grossman School of Medicine. “This work has been made possible through the collaborative efforts between NYU Langone Health and Micronoma. This is a promising area of research that we expect to be important in our efforts to diagnose early-stage lung cancer and risk stratify them.”
For more information about microbiome-driven cancer diagnostics and the OncobiotaLUNG platform, please go to www.micronoma.com.
Micronoma is the first cancer-detection company utilizing signals from circulating microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology. Micronoma was founded in 2019 by leaders in microbiome research with the goal of advancing early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients’ needs are met by their clinicians at the earliest stage for a better chance to live longer, healthier lives. The company is headquartered in San Diego, California.